Create Medicines raised $122 million in a Series B financing to advance its in vivo CAR-T platform across autoimmune disease and oncology. The company, formerly known as Myeloid Therapeutics, uses an mRNA-LNP approach designed to reprogram immune cells inside the body with a goal of enabling repeat dosing and eliminating the ex vivo manufacturing bottleneck. The funding co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners supported a pipeline that includes CRT-402, a CD19-targeted in vivo CAR-T for autoimmune indications, and an additional program targeting CD19 and BCMA. In oncology, Create is pushing MT-303 in hepatocellular carcinoma following early responses. Create disclosed that it has dosed more than 50 patients across its clinical programs, and the company framed the capital raise as runway extension rather than a reset, emphasizing continued internal manufacturing investment. The proceeds are also intended to keep clinical execution and data generation the central priority. The deal underscores sustained investor appetite for cellular therapies that can be delivered with shorter, scalable “one-day” manufacturing cycles—particularly in autoimmune disease where repeated immune modulation may broaden the therapeutic window.